

# Tian-Li Wang

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5785284/publications.pdf>

Version: 2024-02-01

82  
papers

8,178  
citations

87888

38  
h-index

69250

77  
g-index

85  
all docs

85  
docs citations

85  
times ranked

13805  
citing authors

#	ARTICLE	IF	CITATIONS
1	Detection and localization of surgically resectable cancers with a multi-analyte blood test. <i>Science</i> , 2018, 359, 926-930.	12.6	1,872
2	Frequent Mutations of Chromatin Remodeling Gene <i>ARID1A</i> in Ovarian Clear Cell Carcinoma. <i>Science</i> , 2010, 330, 228-231.	12.6	1,090
3	High grade serous ovarian carcinomas originate in the fallopian tube. <i>Nature Communications</i> , 2017, 8, 1093.	12.8	515
4	Cancer-Associated Mutations in Endometriosis without Cancer. <i>New England Journal of Medicine</i> , 2017, 376, 1835-1848.	27.0	451
5	<i>ARID1A</i> , a Factor That Promotes Formation of SWI/SNF-Mediated Chromatin Remodeling, Is a Tumor Suppressor in Gynecologic Cancers. <i>Cancer Research</i> , 2011, 71, 6718-6727.	0.9	390
6	Notch3 Gene Amplification in Ovarian Cancer. <i>Cancer Research</i> , 2006, 66, 6312-6318.	0.9	257
7	Epigenetic therapy activates type I interferon signaling in murine ovarian cancer to reduce immunosuppression and tumor burden. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, E10981-E10990.	7.1	217
8	The emerging roles of <i>ARID1A</i> in tumor suppression. <i>Cancer Biology and Therapy</i> , 2014, 15, 655-664.	3.4	200
9	Evaluation of liquid from the Papanicolaou test and other liquid biopsies for the detection of endometrial and ovarian cancers. <i>Science Translational Medicine</i> , 2018, 10, .	12.4	178
10	Prevalence of somatic alterations in the colorectal cancer cell genome. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002, 99, 3076-3080.	7.1	174
11	Notch3 Overexpression Is Related to the Recurrence of Ovarian Cancer and Confers Resistance to Carboplatin. <i>American Journal of Pathology</i> , 2010, 177, 1087-1094.	3.8	162
12	Genome-wide reprogramming of the chromatin landscape underlies endocrine therapy resistance in breast cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, E1490-9.	7.1	149
13	Inhibition of Spleen Tyrosine Kinase Potentiates Paclitaxel-Induced Cytotoxicity in Ovarian Cancer Cells by Stabilizing Microtubules. <i>Cancer Cell</i> , 2015, 28, 82-96.	16.8	125
14	PVRIG and PVRL2 Are Induced in Cancer and Inhibit CD8+ T-cell Function. <i>Cancer Immunology Research</i> , 2019, 7, 257-268.	3.4	108
15	Roles of Deletion of <i>Arid1a</i> , a Tumor Suppressor, in Mouse Ovarian Tumorigenesis. <i>Journal of the National Cancer Institute</i> , 2014, 106, .	6.3	105
16	The Origin of Ovarian Cancer Species and Precancerous Landscape. <i>American Journal of Pathology</i> , 2021, 191, 26-39.	3.8	102
17	Human transposon insertion profiling: Analysis, visualization and identification of somatic LINE-1 insertions in ovarian cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, E733-E740.	7.1	86
18	Jagged1 Expression Regulated by Notch3 and Wnt/ $\beta$ -catenin Signaling Pathways in Ovarian Cancer. <i>Oncotarget</i> , 2010, 1, 210-218.	1.8	86

#	ARTICLE	IF	CITATIONS
19	Genomic landscape and evolutionary trajectories of ovarian cancer precursor lesions. <i>Journal of Pathology</i> , 2019, 248, 41-50.	4.5	84
20	Loss of ARID1A in Tumor Cells Renders Selective Vulnerability to Combined Ionizing Radiation and PARP Inhibitor Therapy. <i>Clinical Cancer Research</i> , 2019, 25, 5584-5594.	7.0	80
21	Repurposing Pan-HDAC Inhibitors for ARID1A-Mutated Ovarian Cancer. <i>Cell Reports</i> , 2018, 22, 3393-3400.	6.4	77
22	Primary cytoreductive surgery and adjuvant hormonal monotherapy in women with advanced low-grade serous ovarian carcinoma: Reducing overtreatment without compromising survival?. <i>Gynecologic Oncology</i> , 2017, 147, 85-91.	1.4	74
23	Uncovering the Role of N-Acetyl-Aspartyl-Glutamate as a Glutamate Reservoir in Cancer. <i>Cell Reports</i> , 2019, 27, 491-501.e6.	6.4	73
24	CCNE1 amplification and centrosome number abnormality in serous tubal intraepithelial carcinoma: further evidence supporting its role as a precursor of ovarian high-grade serous carcinoma. <i>Modern Pathology</i> , 2016, 29, 1254-1261.	5.5	72
25	Molecular Classification and Emerging Targeted Therapy in Endometrial Cancer. <i>International Journal of Gynecological Pathology</i> , 2020, 39, 26-35.	1.4	69
26	Identification of <i>Pbx1</i> , a Potential Oncogene, as a Notch3 Target Gene in Ovarian Cancer. <i>Cancer Research</i> , 2008, 68, 8852-8860.	0.9	66
27	Notch3 Interactome Analysis Identified WWP2 as a Negative Regulator of Notch3 Signaling in Ovarian Cancer. <i>PLoS Genetics</i> , 2014, 10, e1004751.	3.5	64
28	Gene expression signatures of primary and metastatic uterine leiomyosarcoma. <i>Human Pathology</i> , 2014, 45, 691-700.	2.0	63
29	Ovarian Cancer Chemoresistance Relies on the Stem Cell Reprogramming Factor PBX1. <i>Cancer Research</i> , 2016, 76, 6351-6361.	0.9	61
30	Defining NOTCH3 Target Genes in Ovarian Cancer. <i>Cancer Research</i> , 2012, 72, 2294-2303.	0.9	57
31	Independent development of endometrial epithelium and stroma within the same endometriosis. <i>Journal of Pathology</i> , 2018, 245, 265-269.	4.5	53
32	Assessing aneuploidy with repetitive element sequencing. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 4858-4863.	7.1	50
33	Mevalonate Pathway Antagonist Suppresses Formation of Serous Tubal Intraepithelial Carcinoma and Ovarian Carcinoma in Mouse Models. <i>Clinical Cancer Research</i> , 2015, 21, 4652-4662.	7.0	48
34	CCNE1 copy-number gain and overexpression identify ovarian clear cell carcinoma with a poor prognosis. <i>Modern Pathology</i> , 2017, 30, 297-303.	5.5	48
35	Fallopian Tube Lesions in Women at High Risk for Ovarian Cancer: A Multicenter Study. <i>Cancer Prevention Research</i> , 2018, 11, 697-706.	1.5	47
36	Inactivating ARID1A Tumor Suppressor Enhances TERT Transcription and Maintains Telomere Length in Cancer Cells. <i>Journal of Biological Chemistry</i> , 2016, 291, 9690-9699.	3.4	45

#	ARTICLE	IF	CITATIONS
37	Inactivation of Arid1a in the endometrium is associated with endometrioid tumorigenesis through transcriptional reprogramming. <i>Nature Communications</i> , 2020, 11, 2717.	12.8	45
38	Inhibition of the MYC-Regulated Glutaminase Metabolic Axis Is an Effective Synthetic Lethal Approach for Treating Chemoresistant Ovarian Cancers. <i>Cancer Research</i> , 2020, 80, 4514-4526.	0.9	44
39	Identification of PBX1 Target Genes in Cancer Cells by Global Mapping of PBX1 Binding Sites. <i>PLoS ONE</i> , 2012, 7, e36054.	2.5	40
40	Methylomic Analysis of Ovarian Cancers Identifies Tumor-Specific Alterations Readily Detectable in Early Precursor Lesions. <i>Clinical Cancer Research</i> , 2018, 24, 6536-6547.	7.0	39
41	Genomic characterization of genes encoding histone acetylation modulator proteins identifies therapeutic targets for cancer treatment. <i>Nature Communications</i> , 2019, 10, 733.	12.8	39
42	Laminin C1 expression by uterine carcinoma cells is associated with tumor progression. <i>Gynecologic Oncology</i> , 2015, 139, 338-344.	1.4	37
43	Loss of ARID1A expression in endometrial samplings is associated with the risk of endometrial carcinoma. <i>Gynecologic Oncology</i> , 2018, 150, 426-431.	1.4	36
44	Long Interspersed Nuclear Element 1 Retrotransposons Become Deregulated during the Development of Ovarian Cancer Precursor Lesions. <i>American Journal of Pathology</i> , 2019, 189, 513-520.	3.8	35
45	Yes-associated protein impacts adherens junction assembly through regulating actin cytoskeleton organization. <i>American Journal of Physiology - Renal Physiology</i> , 2016, 311, G396-G411.	3.4	31
46	Mutant BRAF Induces DNA Strand Breaks, Activates DNA Damage Response Pathway, and Up-Regulates Glucose Transporter-1 in Nontransformed Epithelial Cells. <i>American Journal of Pathology</i> , 2012, 180, 1179-1188.	3.8	29
47	T cell-inflamed phenotype and increased Foxp3 expression in infiltrating T-cells of mismatch-repair deficient endometrial cancers. <i>Modern Pathology</i> , 2019, 32, 576-584.	5.5	29
48	Genome-wide mutation analysis in precancerous lesions of endometrial carcinoma. <i>Journal of Pathology</i> , 2021, 253, 119-128.	4.5	27
49	Endometriosis: benign, malignant, or something in between?. <i>Oncotarget</i> , 2017, 8, 78263-78264.	1.8	27
50	The novel ZIP4 regulation and its role in ovarian cancer. <i>Oncotarget</i> , 2017, 8, 90090-90107.	1.8	27
51	Inhibition of ovarian tumor cell invasiveness by targeting SYK in the tyrosine kinase signaling pathway. <i>Oncogene</i> , 2018, 37, 3778-3789.	5.9	22
52	Identification of the NAC1-Regulated Genes in Ovarian Cancer. <i>American Journal of Pathology</i> , 2014, 184, 133-140.	3.8	21
53	CRNET: an efficient sampling approach to infer functional regulatory networks by integrating large-scale ChIP-seq and time-course RNA-seq data. <i>Bioinformatics</i> , 2018, 34, 1733-1740.	4.1	20
54	Mutation of NRAS is a rare genetic event in ovarian low-grade serous carcinoma. <i>Human Pathology</i> , 2017, 68, 87-91.	2.0	19

#	ARTICLE	IF	CITATIONS
55	Proteome-wide Tyrosine Phosphorylation Analysis Reveals Dysregulated Signaling Pathways in Ovarian Tumors. <i>Molecular and Cellular Proteomics</i> , 2019, 18, 448-460.	3.8	19
56	Loss of ALDH1A1 expression is an early event in the pathogenesis of ovarian high-grade serous carcinoma. <i>Modern Pathology</i> , 2015, 28, 437-445.	5.5	16
57	ChIP-BIT: Bayesian inference of target genes using a novel joint probabilistic model of ChIP-seq profiles. <i>Nucleic Acids Research</i> , 2016, 44, e65-e65.	14.5	15
58	Methylomic Landscapes of Ovarian Cancer Precursor Lesions. <i>Clinical Cancer Research</i> , 2020, 26, 6310-6320.	7.0	15
59	Systems medicine dissection of chr1q-amp reveals a novel PBX1-FOXM1 axis for targeted therapy in multiple myeloma. <i>Blood</i> , 2022, 139, 1939-1953.	1.4	15
60	Epithelial Cells in Endometriosis and Adenomyosis Upregulate STING Expression. <i>Reproductive Sciences</i> , 2020, 27, 1276-1284.	2.5	14
61	Elucidating the pathogenesis of synchronous and metachronous tumors in a woman with endometrioid carcinomas using a whole-exome sequencing approach. <i>Journal of Physical Education and Sports Management</i> , 2017, 3, a001693.	1.2	12
62	Development of small molecule inhibitors targeting PBX1 transcription signaling as a novel cancer therapeutic strategy. <i>IScience</i> , 2021, 24, 103297.	4.1	12
63	BRAFV600E-mutated ovarian serous borderline tumors are at relatively low risk for progression to serous carcinoma. <i>Oncotarget</i> , 2019, 10, 6870-6878.	1.8	10
64	Spleen tyrosine kinase activity regulates epidermal growth factor receptor signaling pathway in ovarian cancer. <i>EBioMedicine</i> , 2019, 47, 184-194.	6.1	9
65	A novel human endometrial epithelial cell line for modeling gynecological diseases and for drug screening. <i>Laboratory Investigation</i> , 2021, 101, 1505-1512.	3.7	9
66	Characterization of Primary Cilia in Normal Fallopian Tube Epithelium and Serous Tubal Intraepithelial Carcinoma. <i>International Journal of Gynecological Cancer</i> , 2018, 28, 1535-1544.	2.5	8
67	A Novel ZIP4-HDAC4-VEGFA Axis in High-Grade Serous Ovarian Cancer. <i>Cancers</i> , 2021, 13, 3821.	3.7	8
68	Mutation and methylation profiles of ectopic and eutopic endometrial tissues. <i>Journal of Pathology</i> , 2021, 255, 387-398.	4.5	8
69	Sparselso: a novel Bayesian approach to identify alternatively spliced isoforms from RNA-seq data. <i>Bioinformatics</i> , 2018, 34, 56-63.	4.1	7
70	Protein kinase RNA-activated controls mitotic progression and determines paclitaxel chemosensitivity through B-cell lymphoma 2 in ovarian cancer. <i>Oncogene</i> , 2021, 40, 6772-6785.	5.9	7
71	NAC1 attenuates BCL6 negative autoregulation and functions as a BCL6 coactivator of FOXQ1 transcription in cancer cells. <i>Aging</i> , 2020, 12, 9275-9291.	3.1	6
72	Biomarker Identification by Knowledge-Driven Multi-Level ICA and Motif Analysis. , 2007, , .		5

#	ARTICLE	IF	CITATIONS
73	Reply to Haffner et al.: DNA hypomethylation renders tumors more immunogenic. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E8583-E8584.	7.1	5
74	Targeting glutamine metabolism enhances responses to platinum-based chemotherapy in triple-negative breast cancers (TNBC). Genes and Diseases, 2022, 9, 1408-1411.	3.4	5
75	Detecting aberrant signal transduction pathways from high-throughput data using GIST algorithm. , 2012, , .		2
76	Molecular Genetic Markers in Female Reproductive Cancers. Journal of Oncology, 2010, 2010, 1-2.	1.3	1
77	Expression of Cell Competition Markers at the Interface between p53 Signature and Normal Epithelium in the Human Fallopian Tube. PLoS ONE, 2016, 11, e0156069.	2.5	1
78	Cytomorphologic and molecular analyses of fallopian tube fimbrial brushings for diagnosis of serous tubal intraepithelial carcinoma. Cancer Cytopathology, 2019, 127, 192-201.	2.4	1
79	IntAPT: integrated assembly of phenotype-specific transcripts from multiple RNA-seq profiles. Bioinformatics, 2021, 37, 650-658.	4.1	1
80	RNA-sequencing reveals immunotherapy targets in gynecological cancer.. Journal of Clinical Oncology, 2019, 37, 8-8.	1.6	1
81	Targeting the Notch signaling pathway in cancer stem cells. , 0, , 128-138.		0
82	Analyzing DNA Copy Number Changes Using Fused Margin Regression. , 2009, , .		0